BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 19318561)

  • 1. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
    Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
    Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
    Zheng Y; Izumi K; Yao JL; Miyamoto H
    Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
    Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
    Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
    Paliouras M; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
    Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
    Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
    Jia L; Coetzee GA
    Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
    Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells.
    Gravina GL; Festuccia C; Angelucci A; Poletti A; Capuano D; Vicentini C; Motta M; Bologna M
    Int J Oncol; 2004 Jul; 25(1):97-104. PubMed ID: 15201994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.
    Seth D; Shaw K; Jazayeri J; Leedman PJ
    Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines.
    Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E
    J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.
    Qin HR; Iliopoulos D; Nakamura T; Costinean S; Volinia S; Druck T; Sun J; Okumura H; Huebner K
    Mol Cancer Res; 2007 Sep; 5(9):957-65. PubMed ID: 17704139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
    J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.